2022–2023 mpox outbreak in Israel
Overview of the mpox outbreak in Israel
2022–2023 mpox outbreak in Israel[edit]
The 2022–2023 mpox outbreak in Israel is part of the global 2022–2023 mpox outbreak, which saw a significant rise in cases of mpox (formerly known as monkeypox) outside of its traditional endemic regions in Africa. The outbreak in Israel began in May 2022 and has been closely monitored by health authorities.
Background[edit]
Mpox is a viral disease caused by the monkeypox virus, a member of the Orthopoxvirus genus. The disease is characterized by symptoms such as fever, headache, muscle aches, and a distinctive rash that progresses through several stages. The virus is transmitted through close contact with infected individuals or contaminated materials.
Initial Cases[edit]
The first case of mpox in Israel was reported in May 2022. The patient had recently traveled to Western Europe, where several other cases had been identified. This initial case prompted the Israeli Ministry of Health to issue alerts and guidelines to healthcare providers across the country.
Spread and Containment[edit]
Following the initial case, additional cases were identified, primarily among individuals who had traveled internationally or had close contact with confirmed cases. The Israeli government implemented measures to contain the outbreak, including contact tracing, isolation of confirmed cases, and public awareness campaigns.
Public Health Response[edit]
The Israeli Ministry of Health coordinated with international health organizations to monitor the outbreak and implement control measures. Vaccination campaigns were initiated, targeting high-risk groups, including healthcare workers and individuals with known exposure to the virus.
Impact on Public Health[edit]
The outbreak highlighted the need for robust public health infrastructure and international cooperation in managing infectious diseases. It also underscored the importance of rapid response and effective communication in preventing the spread of emerging infectious diseases.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian